Ozempic Results After One Year: What Long-Term Use Looks Like

Last reviewed: June 30, 2026

Last updated: June 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

After 12 months of consistent semaglutide use, patients typically experience cumulative metabolic shifts that go deeper than initial weight loss numbers suggest. Research from the STEP trials demonstrates that people using GLP-1 therapy maintain meaningful results throughout the year, with many experiencing continued improvements in blood sugar regulation, appetite control, and cardiovascular markers alongside weight reduction.

Average Weight Loss After 12 Months of Semaglutide

Clinical data shows that people following a consistent semaglutide regimen for one full year typically achieve cumulative weight reductions between 15% and 22% of their starting body weight. This translates to roughly 30 to 50 pounds for someone beginning treatment at 200 pounds, though individual results depend on baseline weight, dose progression, and lifestyle factors. The majority of this loss concentrates in the first six months, but the second half of the year often brings stabilization rather than weight regain—a critical distinction from many traditional diet approaches.

Month-to-month progression rarely follows a straight line downward. Most patients experience rapid initial drops during weeks 4-12, then a gradual plateau around month 4-5, followed by continued slower losses through month 12. This pattern reflects the body adjusting to the medication while sustained appetite suppression and improved satiety signals keep overall calorie intake lower without requiring restrictive willpower.

How Metabolic Health Improves Beyond the Scale

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Cardiovascular risk markers also shift meaningfully over 12 months. Blood pressure often decreases by 5-10 mmHg, triglycerides drop in many patients, and inflammation markers like C-reactive protein improve. These metabolic wins remain even if someone's weight plateaus, meaning the health benefit continues accumulating throughout the year independently of the scale.

What Happens to Appetite and Food Preferences During Year One

By the 12-month mark, many patients report that appetite suppression becomes their baseline rather than a side effect. The constant, moderate reduction in hunger signals that feels intense during month two gradually becomes normalized, allowing people to eat smaller portions without feeling deprived. Simultaneously, food preferences often shift—high-fat, high-sugar options that triggered cravings before therapy feel less appealing, while protein-rich and whole-food choices become more satisfying with smaller quantities.

Sustained appetite control is semaglutide's longest-lasting benefit because the medication continues working the same way throughout the year. The GLP-1 receptor remains engaged, gastric emptying stays modulated, and satiety signals persist. This consistency means that year-one results don't depend on willpower erosion or mounting cravings—the biological support remains constant, making weight maintenance easier than it would be after restrictive dieting alone.

Long-Term Sustainability and What Changes After Month 12

Research on extended semaglutide use beyond one year shows that weight stabilization is the norm when people continue their medication and lifestyle practices. Weight regain happens rapidly after stopping semaglutide because appetite signals and metabolic rate return to baseline within weeks, but patients who remain on therapy maintain their gains. This reality makes semaglutide more accurately described as a chronic disease management tool rather than a short-term intervention, similar to how blood pressure or diabetes medications work long-term.

The PlexusDx Precision Peptide Genetic Test analyzes FTO (rs9939609) and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Ozempic or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How much weight can I realistically lose in one year on semaglutide?

Clinical trials show average weight loss between 15-22% of starting body weight over 12 months, with most loss occurring in the first six months. Individual results vary based on starting weight, dose escalation, and adherence to medication plus lifestyle changes like increased protein and movement.

Will my blood sugar improve if I'm prediabetic after one year of semaglutide?

Yes—research consistently demonstrates improvements in fasting glucose and A1C levels within 6-9 months, often moving prediabetic patients into normal ranges. These benefits reflect semaglutide's direct effects on pancreatic insulin secretion and glucose handling, not just weight loss.

What does semaglutide cost at PlexusDx, and is there a flat per-compound pricing increase?

PlexusDx Compounded Semaglutide Injection is $189/mo month-to-month (or $149/mo on the 6-month plan) across all dose levels—your dose may need to go up, but your price won't. PlexusDx serves all 50 states with no insurance required, no membership fee, and HSA/FSA eligibility for cost savings.

What happens to my weight if I stop semaglutide after one year?

Weight regain typically begins within weeks of stopping because appetite signals and metabolic rate return to baseline. Most people regain 50% or more of lost weight within 1-2 years post-discontinuation, which is why semaglutide works best as a sustained therapy rather than a short-term program.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to Ozempic or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Weight Loss Drugs Like Ozempic
• How Do Genetics Affect Short Term Vs Long Term Memory
• How Long To Get Mthfr Test Results
• Lifemd Ozempic

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.